… of sacubitril and 26 mg of valsartan, 49 mg of sacubitril and 51 mg of valsartan and 97 mg of
sacubitril and 103 mg of valsartan. … of valsartan in combination is higher than valsartan given …

Sacubitril/valsartan (SV) is a first in class dual action molecule of the neprilysin (NEP) … prodrug
sacubitril (AHU377) and the angiotensin II receptor (Ang-II) type I antagonist valsartan.[1] It …

… latest international guidelines were issued, new evidence for … , we reviewed the current
evidence on efficacy and safety of S… Based on the available evidence, a wider and earlier use of S…

… compelling evidence for the CV benefit of sacubitril/valsartan … cardioprotective effects of
sacubitril/valsartan, while studies … trial, evidence for the efficacy of sacubitril/valsartan in various …

… evidence-based contemporary medical therapy. Our review underlines the increasing body
of evidence supporting the efficacy of sacubitril/valsartan, … of sacubitril/valsartan in the latest …

… We present the evidence of the ability of sacubitril/valsartan to reverse left ventricular
remodeling in HFrEF or HFpEF patients in Supplementary Table 3. We also discussed the effects of …

… found no evidence of an effect of sacubitril/valsartan in HFpEF participants. Sacubitril/valsartan …
Our results showed no evidence of a difference between sacubitril/valsartan and control …

… evidence, together with the recommendations of the latest clinical guidelines, position
sacubitril/valsartan … In conclusion, there is sufficient evidence that sacubitril/valsartan has a …

… The PROVE-HF research adds to the growing body of evidence supporting reversible cardiac
… Management of HF according to latest guideline recommendations is illustrated in the …

… and wall stretch, sacubitril/valsartan has the potential to … no clear evidence yet that
sacubitril/valsartan improves ejection … antiarrhythmic benefit of sacubitril/valsartan may come from …